{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:36:21Z","timestamp":1790840181903,"version":"4.1.0"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD160 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein expressed on cytotoxic natural killer (NK) cells and T-cell subsets. It plays a crucial role in the activation of NK-cell cytotoxicity and cytokine production. It also modulates the immune system and is involved in some pathologies, such as cancer. CD160 is abnormally expressed in B-cell chronic lymphocytic leukemia (CLL) but not expressed in normal B lymphocytes. Its expression in CLL enhances tumor cell proliferation and resistance to apoptosis. CD160 is also a potential prognostic marker for the detection of minimal residual disease (MRD) in CLL, which is important for the\u00a0clinical management of CLL, the prevention of disease relapse, and the achievement of complete remission. In this review, we present an overview of CD160 and its involvement in the pathophysiology of CLL. We also discuss its use as a prognostic marker for the assessment of MRD in CLL.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1028013","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T06:41:06Z","timestamp":1667803266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["CD160 receptor in CLL: Current state and future avenues"],"prefix":"10.3389","volume":"13","author":[{"given":"Loubna","family":"Oumeslakht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-ilah","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Bensussan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Ben Mkaddem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.3.1121","article-title":"A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity","volume":"178","author":"Ma\u00efza","year":"1993","journal-title":"J Exp Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.012681099","article-title":"Engagement of CD160 receptor by HLA-c is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity","volume":"99","author":"Le Bouteiller","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.9.5349","article-title":"Cutting edge: Engagement of CD160 by its HLA-c physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset","volume":"173","author":"Barakonyi","year":"2004","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ni1554","article-title":"CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator","volume":"9","author":"Cai","year":"2008","journal-title":"Nat Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0217-y","article-title":"CD160 isoforms and regulation of CD4 and CD8 T-cell responses","volume":"12","author":"El-Far","year":"2014","journal-title":"J Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/14.5.445","article-title":"BY55\/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression","volume":"14","author":"Nikolova","year":"2002","journal-title":"Int Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1167\/iovs.18-24021","article-title":"CD160 expression in retinal vessels is associated with retinal neovascular diseases","volume":"59","author":"Henry","year":"2018","journal-title":"Investig Opthalmol Vis Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02188","article-title":"CD160 plays a protective role during chronic infection by enhancing both functionalities and proliferative capacity of CD8+ T cells","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.1800039","article-title":"CD160 stimulates CD8 + T cell responses and is required for optimal protective immunity to listeria monocytogenes","volume":"2","author":"Tan","year":"2018","journal-title":"ImmunoHorizons"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00261","article-title":"Aberrant expressions of Co-stimulatory and Co-inhibitory molecules in autoimmune diseases","volume":"10","author":"He","year":"2019","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.immuni.2022.08.007","article-title":"Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling","volume":"55","author":"Pawlak","year":"2022","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12967-015-0564-3","article-title":"Increased CD160 expression on circulating natural killer cells in atherogenesis","volume":"13","author":"Zuo","year":"2015","journal-title":"J Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002840","article-title":"CD160 and PD-1 Co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction","volume":"8","author":"Peretz","year":"2012","journal-title":"PloS Pathog"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.854432","article-title":"CD160 promotes NK cell functions by upregulating glucose metabolism and negatively correlates with HIV disease progression","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.09.084","article-title":"CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection","volume":"453","author":"Chibueze","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.927519","article-title":"The association between breast cancer and blood-based methylation of CD160, ISYNA1 and RAD51B in the Chinese population","volume":"13","author":"Liu","year":"2022","journal-title":"Front Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100810","article-title":"A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor","volume":"208","author":"Chabot","year":"2011","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03199-0","article-title":"The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma","volume":"71","author":"Gauci","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334326","article-title":"Differential and tumor-specific expression of CD160 in b-cell malignancies","volume":"118","author":"Farren","year":"2011","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0822","article-title":"Clinical implications of novel genomic discoveries in chronic lymphocytic leukemia","volume":"35","author":"Lazarian","year":"2017","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0028-4","article-title":"The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia","volume":"24","author":"Beekman","year":"2018","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia b cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1\u03b1","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood.V130.Suppl_1.3007.3007","article-title":"Nurse-like cells express high-levels of Wnt5a, which induces ROR1-dependent signaling that promotes migration and survival of neoplastic cells in chronic lymphocytic leukemia","volume":"130","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12572","DOI":"10.1038\/s41598-020-69307-1","article-title":"BDNF belongs to the nurse-like cell secretome and supports survival of b chronic lymphocytic leukemia cells","volume":"10","author":"Talbot","year":"2020","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01519-y","article-title":"Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures","volume":"36","author":"Vaca","year":"2022","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1634","article-title":"Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-\u03baB activation and de novo gene transcription","volume":"70","author":"Buggins","year":"2010","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102066","article-title":"Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L","volume":"188","author":"Cols","year":"2012","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.humpath.2011.02.027","article-title":"Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3","volume":"42","author":"Badoux","year":"2011","journal-title":"Hum Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269894","article-title":"Platelet-derived growth factor (PDGF)\u2013PDGF receptor interaction activates bone marrow\u2013derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch","volume":"116","author":"Ding","year":"2010","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1371399","article-title":"TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia","volume":"7","author":"Catakovic","year":"2018","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96610","article-title":"CD84 regulates PD-1\/PD-L1 expression and function in chronic lymphocytic leukemia","volume":"128","author":"Lewinsky","year":"2018","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and b-cell receptor signaling in chronic lymphocytic leukemia: Implications for disease pathogenesis and treatment","volume":"1863","author":"ten Hacken","year":"2016","journal-title":"Biochim Biophys Acta - Mol Cell Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-Cells in chronic lymphocytic leukemia: Guardians or drivers of disease","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1660972","article-title":"CD8 + T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion","volume":"61","author":"Lla\u00f3 Cid","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy","volume":"112","author":"Muzio","year":"2008","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0026","article-title":"B-cell receptor signaling regulates metabolism in chronic lymphocytic leukemia","volume":"15","author":"Vangapandu","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36853-8","article-title":"BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo","volume":"9","author":"Schleiss","year":"2019","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009960","article-title":"ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia","volume":"137","author":"Chen","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-12-0415-T","article-title":"LCK is an important mediator of b-cell receptor signaling in chronic lymphocytic leukemia cells","volume":"11","author":"Talab","year":"2013","journal-title":"Mol Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.42","article-title":"CD5 expression promotes IL-10 production through activation of the MAPK\/Erk pathway and upregulation of TRPC1 channels in b lymphocytes","volume":"15","author":"Garaud","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08","article-title":"CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Sk\u00e5nland","year":"2021","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41408-021-00556-7","article-title":"Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany","volume":"11","author":"Kaj\u00fcter","year":"2021","journal-title":"Blood Cancer J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2973-2","article-title":"Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib","volume":"96","author":"Kaur","year":"2017","journal-title":"Ann Hematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.92","article-title":"Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia","volume":"5","author":"Farren","year":"2015","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm005","article-title":"CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment","volume":"19","author":"Rabot","year":"2007","journal-title":"Int Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.52","article-title":"Identification and analysis of the human CD160 promoter: implication of a potential AML-1 binding site in promoter activation","volume":"10","author":"Schmitt","year":"2009","journal-title":"Genes Immun"},{"key":"B57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4049\/jimmunol.182.1.63","article-title":"Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation","volume":"182","author":"Giustiniani","year":"2009","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1293","article-title":"A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity","volume":"178","author":"Giustiniani","year":"2007","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.161.6.2780","article-title":"Cloning of BY55, a novel ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes","volume":"161","author":"Anumanthan","year":"1998","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2011.02.003","article-title":"CD160: A unique activating NK cell receptor","volume":"138","author":"Le Bouteiller","year":"2011","journal-title":"Immunol Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-019919","article-title":"Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells","volume":"108","author":"Fons","year":"2006","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.imlet.2006.04.006","article-title":"Characterization of murine CD160+ CD8+ T lymphocytes","volume":"106","author":"Tsujimura","year":"2006","journal-title":"Immunol Lett"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.412","article-title":"Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160","volume":"131","author":"Ortonne","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131601","article-title":"CD160 is essential for NK-mediated IFN-\u03b3 production","volume":"212","author":"Tu","year":"2015","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02500-3","article-title":"CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer","volume":"69","author":"Liu","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1167\/iovs.18-24024","article-title":"Anti-CD160, alone or in combination with bevacizumab, is a potent inhibitor of ocular neovascularization in rabbit and monkey models","volume":"59","author":"Menguy","year":"2018","journal-title":"Investig Opthalmol Vis Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700680","article-title":"Identification of a novel CD160+CD4+ T-lymphocyte subset in the skin: A possible role for CD160 in skin inflammation","volume":"127","author":"Abecassis","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22512","article-title":"Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4 + T-lymphocyte subset in normal and mycosis fungoides skin","volume":"85","author":"Sako","year":"2014","journal-title":"Cytom Part A"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/ni0208-122","article-title":"CD160 and BTLA: LIGHTs out for CD4+ T cells","volume":"9","author":"Kaye","year":"2008","journal-title":"Nat Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.09.018","article-title":"Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT","volume":"413","author":"Kojima","year":"2011","journal-title":"J Mol Biol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0241-1","article-title":"HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT","volume":"16","author":"Rodriguez-Barbosa","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1038\/s41467-019-10320-y","article-title":"CD160 serves as a negative regulator of NKT cells in acute hepatic injury","volume":"10","author":"Kim","year":"2019","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4426","article-title":"Murine CD160, ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation","volume":"175","author":"Maeda","year":"2005","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.3.1223","article-title":"Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells","volume":"162","author":"Agrawal","year":"1999","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.str.2019.05.010","article-title":"Structural basis of CD160:HVEM recognition","volume":"27","author":"Liu","year":"2019","journal-title":"Structure"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00355","article-title":"IL-15\u2013PI3K\u2013AKT\u2013mTOR: A critical pathway in the life journey of natural killer cells","volume":"6","author":"Ali","year":"2015","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/80859","article-title":"Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells","volume":"1","author":"Jiang","year":"2000","journal-title":"Nat Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501783","article-title":"Metabolic reprogramming supports IFN-\u03b3 production by CD56 bright NK cells","volume":"196","author":"Keating","year":"2016","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401558","article-title":"mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function","volume":"193","author":"Donnelly","year":"2014","journal-title":"J Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.921212","article-title":"Human hepatic CD56bright NK cells display a tissue-resident transcriptional profile and enhanced ability to kill allogenic CD8+ T cells","volume":"13","author":"Jameson","year":"2022","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer\u2013natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2006.07.004","article-title":"What is natural in natural killer cells","volume":"107","author":"Vivier","year":"2006","journal-title":"Immunol Lett"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: Integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.arcmed.2016.02.001","article-title":"Overexpression of CD158 and NKG2A inhibitory receptors and underexpression of NKG2D and NKp46 activating receptors on NK cells in acute myeloid leukemia","volume":"47","author":"Sandoval-Borrego","year":"2016","journal-title":"Arch Med Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.12097","article-title":"NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma","volume":"7","author":"Parry","year":"2016","journal-title":"Oncotarget"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1049","article-title":"Reduced CD160 expression contributes to impaired NK-cell function and poor clinical outcomes in patients with HCC","volume":"78","author":"Sun","year":"2018","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/ni944","article-title":"BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1","volume":"4","author":"Watanabe","year":"2003","journal-title":"Nat Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200635935","article-title":"The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function","volume":"36","author":"Rey","year":"2006","journal-title":"Eur J Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1172\/JCI41811","article-title":"Putting the brakes on BTLA in T cell-mediated cancer immunotherapy","volume":"120","author":"Paulos","year":"2010","journal-title":"J Clin Invest"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002189","article-title":"Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia","volume":"9","author":"Bozorgmehr","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers ( IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am J Hematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24808","article-title":"IGHV mutational status testing in chronic lymphocytic leukemia","volume":"92","author":"Crombie","year":"2017","journal-title":"Am J Hematol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2262","article-title":"Somatically mutated ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"Tobin","year":"2002","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated ig V h genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.179","article-title":"The tyrosine kinase syk regulates the survival of chronic lymphocytic leukemia b cells through PKC and proteasome-dependent regulation of mcl-1 expression","volume":"28","author":"Baudot","year":"2009","journal-title":"Oncogene"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3390","article-title":"Expression of the T-Cell\u2013specific tyrosine kinase lck in normal b-1 cells and in chronic lymphocytic leukemia b cells","volume":"91","author":"Majolini","year":"1998","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic b cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115717","article-title":"CD23 antigen regulation and signaling in chronic lymphocytic leukemia","volume":"89","author":"Fournier","year":"1992","journal-title":"J Clin Invest"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood","article-title":"Lower levels of surface b-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the and CD79a chains","volume":"105","author":"Vuillier","year":"2005","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.152","article-title":"Lyn-Mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of b-cell chronic lymphocytic leukemia cells","volume":"25","author":"Tibaldi","year":"2011","journal-title":"Leukemia"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.5.883","article-title":"CD5 maintains tolerance in anergic b cells","volume":"191","author":"Hippen","year":"2000","journal-title":"J Exp Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28086","article-title":"Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia","volume":"234","author":"Wang","year":"2019","journal-title":"J Cell Physiol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.151.3.483","article-title":"Akt regulates cell survival and apoptosis at a postmitochondrial level","volume":"151","author":"Zhou","year":"2000","journal-title":"J Cell Biol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04679.x","article-title":"Role of the microenvironment in chronic lymphocytic leukaemia","volume":"123","author":"Caligaris-Cappio","year":"2003","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612244","article-title":"T Cells in chronic lymphocytic leukemia: A two-edged sword","volume":"11","author":"Vlachonikola","year":"2021","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other b cell malignancies: Insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0096","article-title":"Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia b-cell activation and proliferation","volume":"4","author":"Heinig","year":"2014","journal-title":"Cancer Discovery"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes b-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.3390\/ijms22136665","article-title":"Nk cells in chronic lymphocytic leukemia and their therapeutic implications","volume":"22","author":"Sportoletti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6545921","article-title":"Abnormal expression of BTLA and CTLA-4 immune checkpoint molecules in chronic lymphocytic leukemia patients","volume":"2020","author":"Karabon","year":"2020","journal-title":"J Immunol Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000203709","article-title":"Defective natural killer cell activity in b-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-\u03b1","volume":"96","author":"Katrinakis","year":"1996","journal-title":"Acta Haematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/science.1103478","article-title":"Natural killer cell signaling pathways","volume":"306","author":"Vivier","year":"2004","journal-title":"Sci (80- )"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9624-5","article-title":"Primary b-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy","volume":"32","author":"Veuillen","year":"2012","journal-title":"J Clin Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/leu.2008.15","article-title":"NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G","volume":"22","author":"Maki","year":"2008","journal-title":"Leukemia"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2018.1463508","article-title":"Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches","volume":"55","author":"Tomuleasa","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment \u2014 from chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmw006","article-title":"Optimization and validation of an 8-color single-tube assay for the sensitive detection of minimal residual disease in b-cell chronic lymphocytic leukemia detected via flow cytometry","volume":"47","author":"Dowling","year":"2016","journal-title":"Lab Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078339","article-title":"The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells","volume":"8","author":"Hojjat-Farsangi","year":"2013","journal-title":"PloS One"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.597730","article-title":"Highly sensitive and accurate assessment of minimal residual disease in chronic lymphocytic leukemia using the novel CD160-ROR1 assay","volume":"10","author":"Farren","year":"2020","journal-title":"Front Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1028013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T07:54:15Z","timestamp":1678521255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1028013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":130,"alternative-id":["10.3389\/fimmu.2022.1028013"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1028013","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"article-number":"1028013"}}